Đang chuẩn bị liên kết để tải về tài liệu:
Tumor endothelial ELTD1 as a predictive marker for treatment of renal cancer patients with sunitinib

Patients with metastatic renal cell cancer (mRCC) are commonly treated with the tyrosine kinase inhibitor sunitinib, which blocks signalling from vascular endothelial growth factor (VEGF) - and platelet-derived growth factor-receptors, inhibiting development of new blood vessels. | Tumor endothelial ELTD1 as a predictive marker for treatment of renal cancer patients with sunitinib